Gerald Phd Mcmahon Buys 1,000 Shares of Harpoon Therapeutics Inc (NASDAQ:HARP) Stock

Harpoon Therapeutics Inc (NASDAQ:HARP) insider Gerald Phd Mcmahon bought 1,000 shares of the firm’s stock in a transaction on Friday, May 3rd. The shares were bought at an average cost of $10.53 per share, with a total value of $10,530.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Gerald Phd Mcmahon also recently made the following trade(s):

  • On Tuesday, May 14th, Gerald Phd Mcmahon bought 1,000 shares of Harpoon Therapeutics stock. The shares were bought at an average cost of $10.16 per share, with a total value of $10,160.00.
  • On Wednesday, May 8th, Gerald Phd Mcmahon bought 1,000 shares of Harpoon Therapeutics stock. The shares were bought at an average cost of $10.56 per share, with a total value of $10,560.00.

Shares of HARP traded down $0.15 during mid-day trading on Friday, hitting $12.03. The company’s stock had a trading volume of 11,800 shares, compared to its average volume of 44,852. Harpoon Therapeutics Inc has a one year low of $9.07 and a one year high of $17.85. The stock has a market capitalization of $296.83 million and a price-to-earnings ratio of -0.47.

Harpoon Therapeutics (NASDAQ:HARP) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($8.15) earnings per share for the quarter. The firm had revenue of $1.06 million during the quarter, compared to the consensus estimate of $1.22 million. Equities research analysts anticipate that Harpoon Therapeutics Inc will post -2.78 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Fosun International Ltd acquired a new position in shares of Harpoon Therapeutics in the first quarter valued at $3,062,000. MPM Asset Management LLC acquired a new position in shares of Harpoon Therapeutics in the first quarter valued at $42,846,000. New Leaf Venture Partners L.L.C. acquired a new position in shares of Harpoon Therapeutics in the first quarter valued at $21,262,000. BlackRock Inc. acquired a new position in shares of Harpoon Therapeutics in the first quarter valued at $879,000. Finally, Northern Trust Corp acquired a new position in shares of Harpoon Therapeutics in the first quarter valued at $309,000. Institutional investors and hedge funds own 50.04% of the company’s stock.

A number of brokerages have issued reports on HARP. Zacks Investment Research raised Harpoon Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Citigroup reissued a “buy” rating and issued a $23.00 price objective on shares of Harpoon Therapeutics in a research report on Friday, May 24th. Robert W. Baird began coverage on Harpoon Therapeutics in a research report on Monday, April 22nd. They issued an “outperform” rating and a $25.00 price objective for the company. Svb Leerink reissued an “outperform” rating on shares of Harpoon Therapeutics in a research report on Tuesday, March 5th. Finally, Canaccord Genuity began coverage on Harpoon Therapeutics in a research report on Tuesday, March 5th. They issued a “buy” rating and a $24.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $23.75.

COPYRIGHT VIOLATION NOTICE: “Gerald Phd Mcmahon Buys 1,000 Shares of Harpoon Therapeutics Inc (NASDAQ:HARP) Stock” was published by Rockland Register and is the property of of Rockland Register. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://rocklandregister.com/2019/05/31/gerald-phd-mcmahon-buys-1000-shares-of-harpoon-therapeutics-inc-harp-stock.html.

About Harpoon Therapeutics

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer.

Read More: How Important is Technical Analysis of Stocks

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.